IJCS | Volume 33, Nº1, January / February 2019

77 1. Benjamin EJ, Wolf PA,Agostino RBD, Silbershatz H, Kannel WB, Levy D. Clinical Investigation and Reports Impact ofAtrial Fibrillation on the Risk of Death The FraminghamHeart Study. Circulation. 1998;98(10):946–53. 2. KrahnAD, Manfreda J, Tate RB, Mathewson FAL, Cuddy TE. The natural history of atrial fibrillation: Incidence, risk factors, and prognosis in the manitoba follow-up study. Am J Med.1995;98(5):476–84. 3. Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP, et al. Incidence of and Risk Factors forAtrial Fibrillation in OlderAdults. Circulation. 1997;96(7):2455-61. 4. Vidaillet H, Granada JF, Chyou P o-H, Maassen K, Ortiz M, Pulido JN, et al. A population-based study of mortality among patients with atrial fibrillation or flutter. Am J Med [Internet]. 2002;113(5):365–70. 5. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med. 2002;113(5):359–64. 6. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby J V., et al. Prevalence of Diagnosed Atrial Fibrillation in Adults. JAMA. 2001;285(18):2370-75. 7. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–67. 8. Fornari LS, Calderaro D, Nassar IB, Lauretti C, Nakamura L, Bagnatori R, et al. Misuse of antithrombotic therapy in atrial fibrillation patients: Frequent, pervasive and persistent. J Thromb Thrombolysis. 2007 Feb;8:65-71. 9. Dewilde S, Carey IM, Emmas C, Richards N. Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care. Heart. 2006;92(8):1064–70. 10. Wan Y, Heneghan C, Perera R, Roberts N, Hollowell J, Glasziou P, et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: A systematic review. Circ Cardiovasc Qual Outcomes. 2008;1(2):84–91. 11. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. n engl j medJLH); R Perth Hospi-tal N Engl J Med 2011;36510365(10):883–91. 12. Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on atrial fibrillation. Chest. 2010;137(2):263–72. 13. Lip GYH, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: The HAS-BLED (hypertension, abnormal renal/ liver function, stroke, bleeding history or predisposition, labile INR, elderly, drug. J Am Coll Cardiol. 2011;57(2):173–80. 14. Yao X, Gersh BJ, Sangaralingham LR, Kent DM, Shah ND, AbrahamNS, et al. Comparison of the CHA2DS2-VASc, CHADS2, HAS-BLED, ORBIT, and ATRIA Risk Scores in Predicting Non–Vitamin K Antagonist Oral Anticoagulants-Associated Bleeding in Patients WithAtrial Fibrillation. Am J Cardiol 2017;120(9):1549–56. References Geraldes et al. Oral anticoagulation in AF Int J Cardiovasc Sci. 2020;33(1):68-78 Original Article practice, becoming the therapy of choice for patients with AF and contributing decisively to the increase of anticoagulation rates in this group of patients. Despite this important achievement, 13% of eligible patients remainedwithout anticoagulation. Additionally, besides the long-standing historical difficulty of keeping patients on VKA in the narrow therapeutic range, at least 25% of patients using DOACs are exposed to inappropriate doses, compromising its efficacy and safety. The data and reflections described in this study should serve to guide the leaders of our healthcare system and medical societies towards building educational and awareness-raising strategies for health professionals and patients regarding the importance of correct prescription and adherence to anticoagulant therapy in AF. Author contributions Conception and design of the research: Geraldes MFA, Darze ES, Rocha PN. Acquisition of data: Geraldes MFA. Analysis and interpretation of the data: Geraldes MFA, Darze ES, Rocha PN. Statistical analysis: Geraldes MFA, Darze ES, Rocha PN. Writing of the manuscript: Geraldes MFA, Darze ES, Rocha PN. Critical revision of the manuscript for intellectual content: Geraldes MFA, Darze ES, Rocha PN. Potential Conflict of Interest No potential conflict of interest relevant to this article was reported. Sources of Funding There were no external funding sources for this study. Study Association This article is part of the thesis of master submitted by Maria de Fátima de Araújo Geraldes, from Universidade Federal da Bahia . Ethics approval and consent to participate This study was approved by the Ethics Committee of the Prof. Celso Figuerôa, Hospital Santa Izabel under the protocol number 917.116. All the procedures in this study were in accordance with the 1975 Helsinki Declaration, updated in 2013. Informed consent was obtained from all participants included in the study.